The 25th International Symposium on Radiopharmaceutical Sciences (iSRS 2023) was held in Honolulu, Hawaii from May 22 to 26, 2023. In the symposium, experts shared the latest R&D trend of radiopharmaceuticals. The hot topics include New Trends in Radiofluorinations, Artificial Intelligence in Chemistry/Radiochemistry, and Efficient Recipes for the Development of Theranostic Radiopharmaceuticals, etc.
In recent years, with more radiopharmaceuticals put into use, such as Pluvicto (177Lu vipivotide tetraxetan) developed by Novartis, help more patients get new treatment opportunities. Major investment institutions also pay more attention to this field. Integrated diagnosis, treatment and targeted radioligand therapy have become the focus of research and development. At the same time, more enterprises choose the win-win cooperation and joint development. Investment in the research and development of radiopharmaceuticals has entered a rapid growth channel, which indicates that in the near future, the market size of radiopharmaceuticals will expand rapidly. It is expected that the global market size of radiopharmaceuticals will reach $30-40 billion by 2030 (of which the market size of therapeutic radiopharmaceuticals will reach about $24 billion).
In such a booming market, United Well, as the pioneer provider of innovation products in isotopes and radiopharmaceuticals field, will closely follow up the discipline development frontier.
At this symposium, United Well not only brought complete nuclear medicine solutions, including "medical isotopes, radiopharmaceuticals, radioisotope technology and services, clinical and transformation". United Well also demonstrated the company's distinguished capabilities in the field of professional research and development and global supply chain. We are committed to achieve all-round empowerment through global cooperation to facilitate the development of innovative drugs and finally benefit more patients.
